Welcome note

Welcome to Remedica’s latest newsletter.

Remedica’s team has had a very busy start to the year and there is no sign of any slow-down! What has the company been up to over the last three months? This trimester has brought a fresh start, many changes and a series of exciting events and corporate social responsibility (CSR) activities to read about in Remedica’s latest newsletter. Here are the most exciting milestones: the New Year has seen the launching of Remedica’s new, beautifully-designed website, which is updated with the latest information about the company’s products and news and can be found at www.remedica.eu. We are also delighted to share with you that Remedica was selected as the ‘National Winner’ in the European Business Awards, Europe’s most prestigious business competition. The presentation to Remedica’s CEO of the “2018 Game Changers Award” by the Finance Monthly magazine is also an important accomplishment which will hopefully pave the way for an even greater future for the company.

Progress is Remedica’s constant objective and has always helped fuel its business growth. It keeps the company fresh, vibrant and on its toes. It’s only March, and we are looking at a series of activities for 2018 designed to contribute to Remedica’s mission: To alleviate suffering and improve the quality of human life by providing high quality, safe and efficacious pharmaceuticals and other health and care products, promptly and at a reasonable cost.

We hope you enjoy Remedica’s latest newsletter.

Happy reading!
Charalampos Pattihis
Group CEO

Remedica Worldwide

Compania Nationala (CN) Unifarm SA, Romania

Romania is a sovereign state located in south-eastern Europe where it enjoys a temperate continental climate. It shares borders with the Black Sea, Bulgaria, Ukraine, Hungary, Serbia and Moldova and has Bucharest as its capital. Between 2013 and 2016, it experienced a period of good economic growth driven by strong industrial exports and excellent agricultural harvests so that the fiscal deficit was reduced substantially. Encouragingly, industry outperformed all other sectors of the economy in 2016. Exports remained the prime engine of economic growth, led by trade with the European Union (EU), which accounts for roughly 70% of Romania’s trade. Domestic demand was the second driver, due to the mid-2015 cut, from 24% to 9%, in the value-added tax (VAT) levied upon foodstuffs. In 2015, the Government of Romania succeeded in meeting its annual target for the budget deficit and the external deficit remained low, even though it had risen due to increasing imports. For the first time since 1989, inflation was replaced by deflation, allowing a gradual loosening of monetary policy.

Remedica’s local agent in Romania is CN Unifarm SA who commenced trading with Remedica in March 2016, in order to supplant Romania’s shortages of pharmaceutical products. The company, which was founded in 1935, has had a number of different names throughout its many years of experience in the national and international pharmaceutical marketplace. It is currently one of the leading distributors of pharmaceuticals and related healthcare products in Romania.

The company’s main activity is to provide the community of health professionals with pharmaceuticals, sanitary equipment and devices, vaccines, reagents and other products that are either of domestic origin or imported.

Products
CN Unifarm SA sells products, which are available from its company portfolio on an order basis.

Certifications
The company has been granted the ISO 9001: 2008 certification for its quality management system compliance. This has been achieved by continual investment in quality management systems specifically designed so that the medicines are stored and distributed in controlled and monitored conditions and are received by patients with their quality maintained.

Mr. Adrian Ionel, Director General of Compania Nationala (CN) Unifarm SA.
The ABC of Pharmacy

An Introduction to Drug Interactions: Effect of Food and Drink

A drug interaction is considered to have occurred if the effects produced by a drug are altered by another drug, food or drink. The result of an interaction may be an increase or decrease in the activity of the drug which may lead to either toxicity or sub-optimal activity respectively or it may be that the activity of the drug is altered so that unexpected and unwanted effects are produced. Any such effect is known as an adverse drug reaction (ADR) and it is not known with any degree of accuracy how many drug interactions occur per year. There are many reasons for this; for example, if the patient chooses to take other medicines such as those described as over-the-counter which are available from both pharmacy and non-pharmacy outlets, then this will increase the chance of an ADR being produced but it may not be recognised by an individual who appreciates how to report it. Also, if, as is sometimes the case with elderly patients, the number of medicines becomes as high as 15 - 20 per day then an ADR has more potential to occur without necessarily being recognised whereas with, say, two drugs per day the risk is minimal and easily preventable. In the case of all medicines, and especially when more than one is prescribed, the risk-benefit ratio has to be evaluated and as more and more drugs are added to the treatment plan, then this ratio increases.

The inclusion of food and drink in this definition means that before taking a medicine the prescriber and the patient both have a duty to ensure that no potentially dangerous combinations are taken. This should be achieved through verbal warnings by the prescriber or pharmacist, or the placement of written warnings on the dispensed medicine and the patient information leaflet (PIL) that has to be enclosed in the packaging. It is the responsibility of the holder of the medicines licence to ensure that the PIL is both comprehensive and up-to-date since this should be the definitive source of information on this medicine for the patient and the healthcare professionals. As long as all the parties, and especially the patients, read the information contained and follow the instructions closely, then an ADR should not occur.

However, the patients are required to make themselves aware of the contents of foods and pay particular attention to those containing alcohol and caffeine (these two substances along with nicotine will be dealt with in a later article). Also, herbal preparations, which are generally treated as foods in many countries, all contain chemicals which are capable of causing ADRs and so their continued use whilst taking a prescribed medication is probably best avoided as it is not always possible to determine what their ingredients are. Some examples of the herbal (or naturally occurring, as they are often described) products which are known to interact with the effects of prescribed medicines are echinacea, evening primrose oil, kava, ginseng, feverfew, ginkgo biloba, green tea and ginger, to name but a few.

Interaction with Foods

When a drug is swallowed by a patient in the fed state (immediately after a meal) this can have a significant effect on its fate because gastric emptying and gastrointestinal transit will be slowed. Normally, the presence of food will delay the absorption of the drug although it may not alter the total amount of the drug that is absorbed. Experience with a drug will allow the manufacturers and the healthcare experts to decide whether it should be taken on an empty stomach or with food and this advice should be followed faithfully since it will help prevent failures in therapy or avoid unwanted side effects. Some examples of medications that should be taken with food are those containing Allopurinol, Bromocriptine, Ritonavir, Metformin, Ibuprofen, Labetalol and Metronidazole: those which should be taken on an empty stomach are the antibiotics Ampicillin, Sulfadiazine, Rifampicin and Tetracycline as well as Alendronate, Perindopril, Didanosine, Zafirlukast and Thyroxine. For the latter examples, if the drugs are given with food, it is usually the interaction and complexation with contents of the food which produces the reduction in absorption.

Since most drugs that are administered by the oral route are absorbed by passive diffusion in an uncharged form then co-administration of any substance which alters the potential of hydrogen (pH) of the stomach contents will have the capacity to alter the absorption of the drug. For example, the well-known drink Diet Coca-Cola contains phosphoric acid and the resultant pH at 3·2 is sufficient to lower gastric pH at such a degree that the absorption of the anti-fungal agent Ketoconazole has been observed to increase by a factor of about 3; in this study the control
was achlorhydria (blocking the secretion of acid producing a high pH) induced by Omeprazole (1). There is some suggestion that the antacid Maalox reduced the absorption of Ketoconazole but this may not have been the result of neutralisation of the stomach acid. Maalox is a suspension of Aluminium and Magnesium Hydroxides both of which could bind some of the Ketoconazole, which would not then be available to be absorbed (2). This reduction in absorption has been shown to occur with fluoroquinolone antibiotics, such as Ciprofloxacin, when they are taken at the same time as calcium-fortified orange juice (3). Perhaps surprisingly, the amount of calcium in dairy products such as whole milk or yogurt is not sufficient enough to cause any problems in the absorption of antibiotics (4) which is why the US Food and Drug Administration Federal Agency (FDA) advises that they can be safely taken with foods (including dairy products) but not with calcium supplements. Other dairy products such as mature cheeses contain levels of the amino acid tyramine which are sufficient to cause a rise in blood pressure. Administration of the class of antidepressant drugs known as monoamine-oxidase inhibitors, which include Phenelzine and Tranylcypromine, can enhance the action of tyramine to a degree that dangerously high levels of blood pressure can be produced. Other foods that have high levels of tyramine are salami, pickled herring, meat extract, bananas, soy beans and soy sauce, broad beans as well as overripe or dried fruit so these should also be avoided.

One of the best-known examples of a common beverage interfering with the fate of a drug is that which involves grapefruit juice. This affects a number of very commonly used medicines such as calcium channel blocking agents, which are used to lower blood pressure, and statins, which are used to reduce the concentration of cholesterol in the blood: both of these medicines are lifesaving. The reason why the juice of the apparently innocent grapefruit has the potential to affect these drugs is that it contains chemical compounds that interfere with the representatives of the cytochrome P450 family of enzymes that are produced by the liver. Their role in the body is to break down (and thus reduce the activity of) about 50% of all drugs that are used therapeutically. If the chemicals contained in the grapefruit juice block the enzyme then the drug will not be broken down so the level in the body will rise to levels that might become dangerous and even toxic (remember that all drugs are toxic if they are present in the body in amounts which exceed the maximum safe dose). Although the maximal effects of the interaction are seen if the medicine and the juice are swallowed together, the effect can occur up to 4 hours after it has been swallowed because the blocking action takes place in the gut. About 85 drugs have been identified that may be affected by the action of grapefruit juice.

Orange juice has been claimed to reduce the absorption of the antibiotic Levofloxacin but in this example, the effect is produced through the inhibition of p-glycoprotein which is found in the wall of intestinal epithelial cells.

Warfarin is the most common anticoagulant used to prevent thromboembolic events after a patient has suffered a heart attack or stroke. The dose of Warfarin has to be adjusted to suit the needs of an individual patient and it has to be continually monitored in order to prevent the subject suffering a haemorrhage if the blood becomes too thin or precipitating another clot if the blood becomes too thick. For blood to clot as normal, for example when an individual cuts a finger, the body requires that their diet includes sufficient vitamin K as this is an essential element of the clotting process. Warfarin is a vitamin K antagonist (i.e., it reduces its effectiveness in the clotting process) so if a patient has been stabilised with respect to the dose then an increase in the intake of vitamin K in the form of foods means that the blood will clot more quickly and may cause a thromboembolic event, such as a stroke. There are numerous foods that are good sources of vitamin K such as spinach, parsley, Brussels sprouts, kale and broccoli and these should be eaten sensibly by patients who are taking Warfarin. The wide use of Warfarin for more than 60 years has shown up in a number of instances where its activity is affected not just by foods and but also by drugs. It will, therefore, be dealt with in more detail in a future article.

As with all of the examples which have been mentioned in this article, there is no need for patients who are taking any of the aforementioned medications to become alarmed and make major changes to their eating habits. For instance, an individual only needs an intake of vitamin K of 85 – 95μg per day and one cup of spinach will provide about 900μg or approximately 10 times the daily need. If a patient ate 1 cup of spinach a day when the dose of Warfarin was set then continuing to eat that amount would have no effect. However, it would not be sensible to stop eating it because this could increase the clotting time and lead to a bleed. Warfarin is one of the most difficult drugs with respect to interactions with other drugs but users should take comfort from the fact that it has been used for more than 60 years and it has been found to be not only effective but also relatively safe. This is due in no small part to the regular monitoring of the blood clotting time and, if necessary adjusting, the dose to keep it within the safe limit.

Finally, modern medicines are designed to be safe and efficacious and not to be dangerous. The patient needs to bear in mind that interactions with other substances are likely to occur and they should make sure that they have obtained all the necessary information before starting a new therapy: if you are in doubt, you should ask a suitably qualified healthcare professional.

References
Health Matters
Honouring the World Kidney Day: 8 March 2018

World Kidney Day is a worldwide campaign which aims to increase awareness on the risk factors, preventive measures, and symptoms of chronic kidney disease (CKD) as well as the ways of reducing its occurrence.

Obesity and kidney disease
Obesity is a condition in which too much fat has been accumulated in an individuals' body to an extent that it may have a negative impact on their health. In 2014, over 600 million people were identified as being overweight globally (http://www.who.int/life-course/news/events/world-kidney-day-2017/en/). By 2025, it has been predicted that globally obesity will affect 21% of women and 18% of men. In many countries, obese adults represent more than one-third of the total population. Being overweight can lead to an early death as it is implicated as a cause in many other diseases such as diabetes, heart disease, hypertension, fatty liver, mental disorders and higher cholesterol blood levels all of which can lead to a poor quality of life.

Obesity is also known to increase the risk of kidney disease since, as has been stated above, it increases hypertension and diabetes, which are the main risk factors for CKD and it also increases the chance of developing end stage renal disease. The kidneys of adults who are obese have to work harder since they need to filter more blood than normal (hyperfiltration) in order to meet increased metabolic demands. Hyperfiltration can cause a loss of kidney function which increases the possibility of developing CKD.

CKD produces a gradual fall in kidney function because each kidney contains approximately a million filters, known as nephrons, which, when damaged, stop working. Healthy nephrons can work harder but only for a short time so if the damage persists, more and more nephrons begin to close down. Once there are too few left the blood cannot be filtered adequately (http://www.who.int/life-course/news/events/world-kidney-day-2017/en/).

Acute kidney injury (AKI) is a sudden loss of kidney function which, in the majority of the cases, lasts only for a short time and may be reversed once the cause has been treated, although in some cases it can also cause long-lasting health problems. People who are overweight have more chance of developing AKI in comparison to those with normal body weight.

Awareness of the risk factors of being obese can help to prevent CKD. Losing weight through exercise and by following a controlled but healthy diet may either prevent or slow down the development of CKD.

References:
http://www.worldkidneyday.org/faqs/chronic-kidney-disease/
Corporate Social Responsibility: Remedica Cares

1) Remedica participated in the Limassol Marathon (photos 1, 2)
Remedica participated in the Limassol International Marathon GSO, which took place on the 17th of March 2018. More than 160 employees participated from the company. Remedica came in 2nd in participation and won the 8th place in the marathon out of 205 companies. Fully accredited by the Association of International Marathons and Distance Races (AIMS), the Limassol Marathon is run on a flat course which follows the coastline of Limassol Bay in the Mediterranean Sea. The starting point of the race was at the centre of Molos Park. Once the starting gun was fired, runners exited Molos Park and ran eastward towards the Enaerios Area all the way to the Western end of Molos Park, where they turned back for the final kilometres returning to Molos Park.

The event had a charitable purpose: handmade gifts were sold during the registration of participants in the marathon and the amount collected was donated to the Non-Governmental Organisation ‘Prosvasi’ – a charity for people with disabilities.

This race hosted 10,000 runners from 200+ teams. It was a great way for friends to run together, teams to bond and organisations to raise funds for the aforementioned cause. The participation costs of the entrants from Remedica were covered by the company.

2) Remedica among the key sponsors of a Fashion and Hair Charity Show Entitled “Hope for Tomorrow” (photo 3)
Remedica was among the key sponsors of a Fashion and Hair Charity show entitled “Hope for Tomorrow” organised by Maison Anna Dorothea on the 31st January 2016 at the Lantiss Carob Mill in Limassol. Dr Michalis Neoptolemou, represented Remedica at this event where he gave an opening speech. The aim of this event was to provide financial assistance for the Paediatric Oncology Clinic of the Archbishop Makarios III Hospital. The event was a great success having accomplished its aim of supporting the Clinic and having offered the participants the opportunity to witness the creativity and skill set showcased during the show.

3) Remedica Attended a Series of Seminars Organised by CSR Cyprus (photo 4)
Remedica participated in a series of workshops organised by CSR Cyprus on the topic of Corporate Social Responsibility (CSR) and its implementation in businesses. The aim of the educational workshops was to provide the participants with the necessary knowledge and methodological tools to enable their businesses to comply with the current requirements for transparency and CSR and to gradually develop and integrate an approach and a strategy for sustainable development.

The workshops were very constructive and helped the participants understand the key concepts of CSR and sustainable development, as well as how to apply them to their respective fields.

4) Participation in the Workshop with the title “The Social Role of the Pharmacist” (photo 5)
The Department of Life Sciences of the European University of Cyprus in collaboration with the World Pharmacists of Cyprus and with the support of the Cyprus Pharmaceutical Association, organised a scientific workshop titled “the Social Role of Pharmacists”. The aim of the workshop was to raise awareness among health professionals about matters relating to volunteering and CSR by promoting action by the industry.

As part of the workshop, Mr Andreas Hadjipanayis, the Marketing Manager and National Sales Manager of Remedica, spoke about the company’s strategy on CSR. In addition, he encouraged participants to incorporate practices that promote social and environmental welfare based on sustainable development.

5) Remedica Organised a Blood Donation Camp for yet another Year (photo 6)
Remedica has, for many years, organised blood donations in which it has encouraged all of its employees to participate. This activity was repeated yet again this year with the aim of boosting the blood bank supplies of the Limassol General Hospital. The blood camp was a great success with more than 70 employees donating blood to help those in need.

6) Financial Support to the “Melathron Agoniston EOKA” (photo 7)
Remedica provided financial support to help fund the Association titled “Melathron Agoniston EOKA” in order to expand and upgrade its facilities. Remedica recognises the importance of the work and contribution of the association to our society and reinforces it by supporting it financially and in other ways. Volunteering and philanthropy are core values of the company. Since its establishment, Remedica has always supported important social causes and has always been there for the disadvantaged groups of society and has committed to continue this tradition. Dr Michalis Neoptolemou, visited the premises of the organisation to make the contribution.
was achlorhydria (blocking the secretion of acid producing a high pH) induced by Omeprazole (1). There is some... above.

Entevirem® is available in the strengths of 0.5mg and 1mg as film-coated tablets.

8) Remedica’s CEO attends UCL’s annual Scholarships and Bursaries Reception (photo 9)
Mr Charalambos Pattihis, Remedica’s CEO, attended the annual Scholarships and Bursaries Reception of the University College London (UCL) where the company offers a scholarship for the MSc Course in Management. The Events Team, in a thank you note to Mr Pattihis, described it as “a great opportunity to celebrate the lives that are transformed and the opportunities that are opened up thanks to Remedica’s support”. They added that “many of UCL’s brightest and best students would not be here without the support of a scholarship or bursary, and it was terrific to hear from two of them, Hira and Kasim, about what their funding has enabled and their passion to make a difference to the world.”

7) Financial help to the Organisation Paraplegic Cyprus - OPAK (photo 8)
As a part of Remedica’s CSR programme, the company offered the Organisation Paraplegic Cyprus (OPAK) financial help for the purchase of a special vehicle to help transfer those who are using wheelchairs. OPAK is an organisation consisting of volunteers with members who, due to trauma or spinal injuries, have lost the ability to move their lower or upper limbs, which brought multiple complications to their health beyond kinetic disabilities. OPAK was founded in 1980 and is one of the first organisations created by people with disabilities with the aim of improving the quality of life of those affected. The General Manager of Remedica, Dr Michalis Neoptolemou, visited the premises of the organisation in February 2018 to make the contribution.

Remedica People
Mr Michael Georgiou, Material Sourcing and Compliance Manager
Mr Michael Georgiou graduated from the American Academy in Nicosia and then completed his bachelor’s degree in Medical Engineering at the University of Bradford, in the United Kingdom. After his graduation and during further training, he acquired the highest levels of recognition in the Lean Six Sigma Business Excellence certifications, being awarded sequentially the “Green Belt”, “Black Belt” and “Master Black Belt”. He speaks three languages: English, Greek, and Arabic.

He started his career in the medical devices industry by designing two prosthetic implants that are used to replace cervical and lumbar discs with the aim of improving the quality of life of patients suffering from spinal stenosis and other spinal disorders. In April 2011, he joined Remedica’s family as Supplier Auditor in the Quality Assurance Department. He currently holds the position of Manager of the Material Sourcing and Compliance Department, which is responsible for the sourcing of raw materials, supplier evaluation and the Current Good Manufacturing Practices (cGMP) audit of all raw material manufacturers, as well coordinating quality compliance projects internally. Since he joined the company, his role has involved travelling all over the world to ensure that Remedica only purchases raw materials from approved manufacturers.

Despite his heavy workload and frequent travels, he continues his studies with the aim of acquiring the following postgraduate degrees within the next six months:
• MSc Certification as a Qualified Person in the Pharmaceutical Industry
• MSc in Procurement Logistics and Supply Chain Management
• MA in International Relations, Global Economy and Strategic Analysis

When asked how he feels about his success, he replied “Success comes with sacrifice, hard work, and commitment to what you love to do. Every day holds a new challenge for all of us with new obstacles that we should commit to overcoming and as long as there is a will, there is a way.”

Our Products
Entevirem® (Entecavir)
Recently, the medicinal product Entevirem® has been approved by the Pharmaceutical Services of the Ministry of Health of Cyprus and more registrations are pending. Entevirem® contains the active substance Entecavir and it is indicated for the treatment of chronic hepatitis B virus in adults and children aged two years and above.

Entevirem® is available in the strengths of 0.5mg and 1mg as film-coated tablets.
Remedica News

1) Remedica, the National Winner in the European Business Awards  (photo 1)
We are delighted to inform you that Remedica has been named ‘National Winner’ in the 2017-18 European Business Awards, Europe’s largest business competition, sponsored by RSM. Remedica was chosen from 2,998 businesses previously identified as ‘Ones to Watch’ in a list of business excellence published in December and selected as a National Winner by a panel of independent judges including senior business leaders, politicians and academics as the best business in Cyprus in the Awards’ category “The Germany Trade & Invest Award for International Expansion”. Remedica will now go on to represent Cyprus in the final stage of the competition. Mr Charalambos Pattihis, CEO of Remedica said: “We’re very proud to have been named ‘National Winner’ in the 2017-18 European Business Awards, which are widely recognised as the showcase for Europe’s most powerful companies”.

2) Remedica’s CEO receives the “2018 Game Changers Award” (photo 2)
We are delighted to share with you that the magazine Finance Monthly presented Mr Charalambos Pattihis, Remedica’s Group CEO, with the “2018 Game Changers Award”. Every year Finance Monthly identifies and honours the most respected companies and individuals in business, the Game Changers. Finance Monthly’s research team draws on the views of thousands of voters including; finance monthly readers, investors, analysts, C-level executives, employees, and media professionals. Following the voting stage and shortlisting rounds, the researchers at Finance Monthly determined the eligibility of each individual based on his or her achievements during the last 12 months as well as examining all submitted materials received through the voting process. Nominations are granted to all industry sectors. The 2018 Game Changers Awards celebrate the success, innovation and strategic vision of some of the world’s most recognised professionals.
More information is available on: goo.gl/OPHrFq

3) We Proudly Present Remedica’s New Website! (photos 3)
We are very pleased to announce the launch of Remedica’s brand-new website! The previous website has been replaced by a completely new design. Along with a new look we have included features that we hope will make visiting the site a quicker, easier and more interactive experience. The new website has a fresh layout and has been made much more user-friendly than the previous one. The homepage will now grant you quick access to frequently visited or important pages. We have also optimised the new design for mobile devices, which will largely facilitate surfing the website. To make sure that you stay abreast of the latest developments at Remedica you can now also keep up-to-date with the news section which will have regular updates. Remedica has also been very active on social media since the start of this year - are you following us yet? We hope you enjoy the new website and we would love to hear what you think about it. Have fun surfing on the new site! You can visit it at www.remedica.eu

4) New Year’s Eve party (photos 4, 5)
Remedica celebrated the New Year by organising a special party dedicated to its employees on the 6th of January. The event was hosted by the General Manager of the company, Dr Michalis Neoptolemou, who welcomed the attendees and expressed his wishes for a healthy, prosperous and creative new year. His address was dedicated to the late founder of Remedica, Mr Chris Pattichis, emphasising the importance of the company’s people, who he described as “Remedica’s biggest asset, who greatly contribute to the development of the company with zeal and effort.” Finally, he referred to a significant success of the company, that of being selected as the best company of the Year in 2017 in the Ascendis Health Group. During the evening, the employees who had worked for more than thirty years in the company were honoured. In charge of the ceremonial part of the evening was the actress Christiana Theodorou and the musical programme was performed by the singers, Hoviç Demirjian, Philippos Konstantinos and Annita Konstantinou who entertained the guests until the early hours of the morning.

5) Succession at the Pharmaceutical Manufacturers Association of Cyprus (Cy.Pha.M.A.)
Remedica’s Group CEO, Mr Charalambos Pattihis, founder and first President of the Pharmaceutical Manufacturers’ Association of Cyprus (Cy.Pha.M.A.), has stepped down from heading the Association after 20 years of service. He is succeeded by Remedica’s General Manager, Dr Michalis Neoptolemou to whom we convey our congratulations and wish him every success in this additional role.
Pattihis Family Scholarship

Remedica offers the Pattihis Family Scholarship for the academic year 2018/19 for the MSc Management degree in the Department of Management Science and Innovation at University College London (UCL).

As well as covering the fees totalling £28,370, the Scholarship includes an offer of employment with Remedica (subject to successful completion of the degree and eligibility).

Remedica, a member of the Ascendis Health Group, is a Cypriot company located in Limassol which exports pharmaceutical products in more than 100 countries. Originally founded in 1960 by Mr. Chris Pattichis as a manufacturer of carbon dioxide, it went through various stages of development and expansion to become specialist in the development, production and sale of high-quality, safe and efficacious pharmaceutical products for human use. Remedica has been bestowed with the Export Award 8 times and has also received the Quality Award, the Enterprise of the Year Award, and an honorary award (Ruban d’Honneur) by the European Business Awards for being one of Europe’s top 10 export companies.